Current Report Filing (8-k)
14 August 2019 - 6:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): August 13, 2019
Protalix
BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Delaware
|
|
001-33357
|
|
65-0643773
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
2 Snunit Street
|
|
20100
|
Science Park, POB 455
|
|
|
Carmiel, Israel
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
|
|
|
|
|
|
Registrant’s telephone number,
including area code +972-4-988-9488
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
¨
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth
company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
☐
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, $0.001 par value
|
|
PLX
|
|
NYSE American
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
On August 13, 2019, Protalix BioTherapeutics, Inc. (the “Company”)
announced that Shlomo Yanai has resigned from the Company’s Board of Directors for personal reasons, effective August 13,
2019. The Company’s Board of Directors
appointed Zeev Bronfeld, a current independent director,
to serve as Chairman of the Board.
A copy of a press release announcing Mr. Yanai’s resignation is filed as Exhibit
99.1 to this Current Report.
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 13, 2019
|
PROTALIX BIOTHERAPEUTICS, INC.
|
|
|
|
By:
|
/s/ Dror
Bashan
|
|
|
Name: Dror Bashan
Title: President and Chief Executive Officer
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Apr 2024 to May 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From May 2023 to May 2024